REPL · Replimune Group, Inc.

The thesis

Replimune is now a commercial company. Its melanoma drug TUDRIQEV won accelerated approval on 6 August 2026 and reached its first patients on 6 October 2026, and early signs from the launch have lifted the shares to a 52-week high. The case depends on how fast doctors take up the drug. The fiscal third-quarter report, expected around February 2027, will give the first revenue figure and settle it.

Replimune reported fiscal second-quarter 2027 results on 28 October 2026, for the quarter ended 30 September 2026. The net loss was $57.1 million, or $0.54 per share, against a consensus estimate of a $0.77 loss (Benzinga). Cash was $307.8 million, helped by an August stock offering that raised about $141.0 million net. The shares rose 18% on the day of the report (ad-hoc-news) and closed at $17.39 on 29 October 2026, the 52-week high in adjusted daily closes.

The narrative is accelerating: new facts arrived in quick succession. The drug went on sale in the US on 1 October 2026, the earnings beat came on 28 October 2026, and Leerink Partners raised its target to $31 on 29 October 2026. The Oncology & immunology group, whose peers include GMAB, KNSA and HALO, has also been heating up again since late October.

Bullish and bearish views on Replimune Group, Inc.

The bull case on Replimune Group, Inc. (REPL), in brief: The label covers advanced cutaneous melanoma that has progressed on anti-PD-1 therapy. The bear case: There is no revenue yet.

Bull case

• The label covers advanced cutaneous melanoma that has progressed on anti-PD-1 therapy. Approval followed two complete response letters and a 10–3 advisory committee vote in favour on 30 July 2026 (AJMC).
• Responses in the trial were durable. In the 140-patient IGNYTE trial, 32.9% of patients had a confirmed response, and responses lasted a median of 33.7 months (AJMC).
• The launch is opening accounts quickly. On 28 October 2026 the company reported more than 15 institutions prescribing and contact with more than 70% of its initial 200 priority accounts. It also cited a category 2A listing in the National Comprehensive Cancer Network (NCCN) guidelines and published payer policies that cover use within the label.
• The drug carries a high price. The list price is $450,000 per course of therapy (28 October 2026 earnings call). The company holds more than one year of inventory, made in its own facility.
• Research and development fell to $34.4 million from $57.9 million (28 October 2026 results release).
• A brokerage raised its target. On 29 October 2026 Leerink Partners kept its Outperform rating and raised its price target to $31 (Benzinga).

Bear case

• There is no revenue yet. Product revenue was zero in the quarter ended 30 September 2026, because the first delivery came on 6 October 2026. The company gives no revenue guidance.
• The approval is conditional. Keeping the approval depends on confirming clinical benefit in IGNYTE-3, a Phase 3 trial whose primary goal is overall survival. As of 28 October 2026 the trial was still enrolling, and the company has not given its size or a readout date.
• Funding has come from new shares. The quarter's weighted average share count was 105.2 million, up from 91.9 million a year earlier. Replimune raised about $141.0 million net in August 2026 and drew $15.0 million from a fourth tranche of its loan facility in September 2026.
• The cash runway is short. The company says its cash will fund operations for "greater than twelve months" from the date of its financial statements (28 October 2026). That is the minimum period the accounting test for a going-concern warning requires.
• The FDA was sceptical until late. FDA reviewers reportedly gave a negative assessment ahead of the 30 July 2026 advisory panel (AJMC). Any further regulatory friction would fall on a stock that has already priced in a working launch.

Price setup

The shares closed at $17.39 on 29 October 2026. That was the 52-week high in split- and dividend-adjusted daily closes. They are up 46.0% over three months.

The 14-day relative strength index (RSI), a momentum gauge, stood at 68.3 on 29 October 2026. Many technical analysts treat readings above 70 as overbought, so the gauge is close to that line. Much of the recent gain came in one session, the 18% rise on 28 October 2026.

The visible signs of crowding are a fast run to a new high and the August 2026 share offering, sold as the stock rose after approval. A daily close below $14.00 would give back most of the rally that followed the report.

Catalysts, next 30 days

• 30 October to 29 November 2026: Company releases show no scheduled company event in this window. Any update on the launch would have to come from investor-conference appearances, and none has been dated.
• ~11 February 2027, est.: Fiscal third-quarter 2027 report, covering the quarter to 31 December 2026. It will carry the first TUDRIQEV sales figure, which is the number the case turns on.

Elapsed catalysts

• IGNYTE-3 and RP2 REVEAL (uveal melanoma): Both trials are enrolling, and the company has given no readout dates as of 28 October 2026. (passed 3d ago)

What would change the view

The case breaks if the launch stalls. One sign would be first-quarter TUDRIQEV revenue in the ~11 February 2027 report that is small next to the $450,000 list price and the 200 priority accounts. Another would be a prescriber count that has barely grown from the more than 15 institutions reported on 28 October 2026. Payers narrowing coverage beyond the label would also weaken it.

A second equity raise soon after the August 2026 offering would show cash burn outrunning sales. So would a cut to the "greater than twelve months" runway statement. Any FDA action on the accelerated approval, or a disclosed delay or enrollment problem in IGNYTE-3, would undercut the conditional approval the case rests on.

On price, a daily close below $14.00 would undo most of the rally after the report and mark the launch re-rating as failed.

What it trades with

Replimune's biggest moves have come from its own regulatory news: the complete response letters, the 30 July 2026 advisory vote and the 6 August 2026 approval. Launch data is now taking over that role. The listed peers make weak comparisons. GMAB and HALO earn revenue from antibody products and royalties, and KNSA is a commercial-stage company in a different disease area, so their quarterly results say little about TUDRIQEV demand. The shares are likely to move with small and mid-cap biotech stocks when investors' appetite for risk shifts. That link would break down if the shares held their gains through a broad biotech sell-off.